Altimmune, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-46.4M | $-11.1M | $-3.4M | $-10.0M | $-11.7M | $-4.9M | $-3.8M | $-34.8M |
| Depreciation & Amortization | — | — | — | — | — | $303.9K | $461.1K | $1.0M |
| Depreciation | $83.8K | $63.1K | $141.6K | $150.0K | $182.5K | $303.9K | $461.1K | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $1.4M | $965.4K | $613.0K | $1.7M | $1.4M | $1.9M | $2.6M | $2.5M |
| Net Cash from Operating Activities | $-20.2M | $-6.4M | $-3.2M | $-8.5M | $-7.2M | $-2.3M | $-7.8M | $-14.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $112.4K | $125.0K | $86.5K | $92.3K | $84.6K | — | $71.4K | $374.6K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $13.7M | — | — | — | — | $67.4K | $1.7M | $2.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $15.8M | — | — | — | — | $3.7M | $5.8M | $21.5M |
| Net Change in Cash | $9.4M | $138.4M | $-3.1M | $8.2M | $-2.2M | $1.5M | $-548.6K | $9.1M |
| Free Cash Flow | $-20.3M | $-6.5M | $-3.3M | $-8.6M | $-7.3M | — | $-7.9M | $-15.2M |